Swiss Medica Inc., Innovative Products That Improve Peoples' Lives

11/24/2003 8:00 AM ET News Release Index

SWISS MEDICA ENTERS INTO DISTRIBUTION AGREEMENT WITH ASENDA PHARMACEUTICAL SUPPLIES

FOR IMMEDIATE RELEASE

Stock Symbol: OTC BB: SWME

November 24, 2003

SWISS MEDICA ENTERS INTO DISTRIBUTION AGREEMENT WITH ASENDA PHARMACEUTICAL SUPPLIES

Toronto, Canada – Swiss Medica Inc. announced today that it has reached an agreement with Asenda to

distribute O24 Penetrating Pain Relief to their extensive network of independent pharmacy retailers.

This relationship will be the first for Swiss Medica in offering O24 Penetrating Pain Relief to the very large

independent pharmacy retail market in Canada. 2002 sales for Asenda were in the hundreds of millions of

dollars.

"Asenda gives us the logistical infrastructure to approach the independent pharmacy market. This will literally

open the mainstream retail channel for our O24 Penetrating Pain product. Just the fact that they are bringing the

product into their warehouse will result in hundreds of new retail clients” said Mike Bain VP of retail sales for

Swiss Medica.

“I am looking forward to partnering with Swiss Medica and their team. I believe they have a unique product that

will add value to our business. I recommend that anyone with chronic pain try 024 and feel the relief, it works for

me!” said Rob Julien, Category Manager Asenda.

About Asenda

Asenda Pharmaceutical Supplies Ltd. is a full-line pharmaceutical wholesale organization, serving over 700

licensed pharmacies and growing in Western Canada. Asenda is widely recognized for superior service,

available six days per week. Asenda is based in Richmond, British Columbia, where they began over 15 years

ago.

About Swiss Medica Inc.

Swiss Medica Inc. is focused on acquiring over-the-counter bioscience products with demonstrated competitive

advantages and increasing their revenues by focused sales and marketing efforts in selected distribution

channels including retail, direct sales, direct response, and e-commerce. Swiss Medica’s mission is to be a world

leader in the acquisition and commercialization of life enhancing bioscience products that improve quality of

lives. Please visit our websites at www.swissmedica.com and

Forward-looking statements in this news release are made pursuant to the "Safe Harbor" provisions of the

United States Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking

statements involve risks and uncertainties, including, without limitation, risks relating to the ability to close

transactions being contemplated, risks related to international sales and potential foreign currency exchange

fluctuations, continued acceptance of Swiss Medica’s services, increased levels of competition, technological

changes, dependence on intellectual property rights and other risks detailed from time to time in Swiss Medica’s

periodic reports filed with the United States Securities and Exchange Commission and other regulatory

authorities.

Investor Relations Contact:

Dave Jones: 705 495 0022